NEXGEL (NXGL) Corporate presentation summary

Strategic review and transformation rationale

• Initial acquisition strategy failed to deliver expected revenue growth and profitability, with consumer products underperforming and manufacturing/commercialization challenges disrupting execution.

• Strategic review found stable revenue from Interfyl and expansion opportunities with Arthrex, but working capital was consumed faster than forecast and cost structure was unsustainable.

• Cost reductions were implemented, but alone were insufficient to unlock asset value; a new integrated approach was needed.

Proposed reorganization and platform vision

• Plan to consolidate Fountainhead LifeSciences' operating assets into a single public company, recapitalize the balance sheet, and raise $5 million in new capital.

• Reorganization aims to align ownership, management, manufacturing, and commercialization, eliminating duplicated infrastructure and fragmented operations.

• The new platform will be surgeon-centric, integrating innovation, training, manufacturing, and commercialization to advance procedural excellence and patient outcomes.

Asset contributions and operational capabilities

• Fountainhead to contribute over $10M in 2026 revenue, biologics and device inventory, cleanrooms, manufacturing equipment, and a 42,000 sq. ft. facility.

• Assets include Sequence LifeScience's tissue processing, NVISION's medical device pipeline, and a cadaver lab for surgeon engagement and training.

• Strategic assets also include an experienced management team and integrated support functions.